.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Management of IgA nephropathy has entered a new era with the arrival of advanced therapies. While SGLT2 inhibitors and RAS inhibitors remain foundational, many patients still face the threat of kidney failure. This recent crossover trial provides exciting data on the role of Atrasentan in IgA nephropathy as an adjunct treatment. Consequently, by targeting specific pathways, this drug offers additional hope for patients with persistent proteinuria.
The study involved 54 adults with IgA nephropathy who were already receiving stable doses of guideline-recommended therapies. In this study, researchers compared the efficacy of 0.75 mg daily atrasentan against a placebo over a 12-week period. Consequently, the results showed a striking difference. Atrasentan led to a 25.3% reduction in the urinary protein-to-creatinine ratio compared to the placebo. Moreover, patients experienced a total 48.1% drop from their baseline levels. These findings clearly indicate that adding atrasentan provides significant clinical benefits beyond current standard treatments.
Safety remains a primary concern when combining multiple potent drugs. Fortunately, the trial demonstrated that the combination was well-tolerated. Specifically, there were no reported cases of heart failure or serious edema. Because SGLT2 inhibitors have diuretic properties, they might mitigate the fluid retention typically associated with endothelin receptor antagonists. Furthermore, most adverse events were mild or moderate in severity. Therefore, clinicians can consider this combination as a safe strategy to further reduce residual risk in high-risk patients.
In summary, this trial confirms that atrasentan is an effective tool for lowering proteinuria. When integrated into a regimen of RAS and SGLT2 inhibitors, it produces a clinically meaningful impact. Consequently, this multi-targeted approach could become the new standard for preserving kidney function in IgA nephropathy.
Atrasentan acts as a selective endothelin-A receptor antagonist. By blocking this pathway, it reduces glomerular pressure and inflammation, which are not fully addressed by SGLT2 or RAS inhibitors alone.
Yes, the safety profile is encouraging. The most common side effects are mild, and the risk of significant fluid retention appears low, especially when used with SGLT2 inhibitors.
Clinical data showed that adding atrasentan to existing therapy can lead to an additional 25.3% reduction in proteinuria compared to standard care alone.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Atrasentan as an adjunct to SGLT2 inhibitors reduces proteinuria by 25.3% in IgA nephropathy patients, according to a recent crossover trial....
3 months ago
The Food Safety and Standards Authority of India (FSSAI) has rejected industry appeals and directed beverage manufacturers to remove the term 'energy drink' and unapproved therapeutic claims within 90 days. This regulation aims to curb misbranding and ensure clear labeling across commercial food products.
Today
Johnson & Johnson announced a $5.5 billion settlement to resolve nearly 69,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. This comprehensive deal covers 99.75% of active claims. Read about the legal strategy, scientific evidence on talc exposure, and clinical counseling for patients.
Today
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
4 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
4 days back
A UK Biobank study of 471,540 participants reveals that metabolic syndrome increases incident gastric cancer risk by 36% (HR=1.36). A positive trend was observed with accumulating metabolic components, with waist circumference showing the strongest association, highlighting modifiable risk targets.
4 days back
